Skip to content

MVA to Improve the Pregnancy Outcome in Aged Infertility Women With Assisted Reproductive Technology

A Single-center Randomized Controlled Trial on Mevalproic Acid Improving Oocyte Quality and Embryo Development in Elderly Infertile Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05788822
Enrollment
148
Registered
2023-03-29
Start date
2022-10-08
Completion date
2025-12-31
Last updated
2023-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female, IVF, Oocyte, Reproductive Disorder

Brief summary

The goal of this clinical trial is to test MVA on improving pregnancy outcome in elderly infertile patients undergoing invitro fertilization (IVF). The main question it aims to answer is whether MVA could improve embryo haploid rate. Participants requested IVF are asked to randomly culture equal numbers of oocyte and embryo with or without MVA. Therefore, sibling oocytes were randomly divided into test group and control group.

Detailed description

After being informed about the study and potential risks, all participants will write the informed contents. This study is a randomized controlled study co compare different treatment methods on the embryo development. Sibling eggs were randomly divided into test group and control group. Specific method of randomization: all the eggs of each subject were distributed into two dishes (dish 1 and dish 2). If the oocyte number is odd, put the extra oocyte into dish 1. Using statistical software, the two dishes were randomly treated as test group and control group. Thus, a random allocation table was generated and a separate random envelope was made for each subject. The random envelope is kept and distributed by the relevant personnel who are not involved in the screening and treatment of subjects and are authorized by the researcher. Each selected subject must open the random envelope. The subjects were subjected to routine ovulation promotion, and then the acquired oocytes and cumulus cell complexes (COCs) were obtained and fertilized in vitro. The test group oocytes were cultured with MVA, while the control oocytes were cultured without MVA. Thus, half of the eggs from each elderly infertile patient were treated with MVA.

Interventions

DIETARY_SUPPLEMENTMevalproic acid

Methovalerate pathway is a metabolism of cholesterol and isoprenoid synthesized from acetyl coenzyme A Pathway, which plays a key role in human health and disease, is also necessary for human cells to maintain normal functions. There are a series of important metabolic intermediates in the mevalproate pathway, such as farnesyl diphosphate and incense Folyl vanillin diphosphates, which modify proteins through isoprene, play an important role in regulating cell function. In addition, the latest research shows that valproic acid, the key metabolic intermediate of valproic acid pathway, being the synthetic precursor of cholesterol and isoprene, it can activate insulin growth factor (IGF)1-R and mTOR signals and maintain cell function by mediating histone function

Sponsors

Nanjing University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
38 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

1. 38 years ≤ age ≤ 42 years; 2. Number of IVF/ICSI cycles ≤ 2

Exclusion criteria

1. Egg donor cycle 2. Chromosome abnormality; 3. Adenomyosis, hysteromyoma, thin endometrium, endometriosis and other uterine diseases; 4. Patients with repeated implantation failure

Design outcomes

Primary

MeasureTime frameDescription
Embryo haploid rateone month after oocyte retrivalPreimplantation genetic testing (PGT) was used to test embryo haploid rate

Countries

China

Contacts

Primary ContactHaixiang Sun, MD
haixiang_sun@nju.edu.cn025-83106666
Backup ContactJie Mei, MD
meijie560@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026